Cervical cancer screening

Edward E. Partridge, Nadeem Abu-Rustum, Susan Campos, Patrick J. Fahey, Benjamin E. Greer, Subodh M. Lele, Richard W. Lieberman, Gary H. Lipscomb, Mark Morgan, Maria Enriqueta R. Nava, R. Kevin Reynolds, Diljeet K. Singh, Karen Smith-McCune, Nelson Teng, Cornelia Liu Trimble, Fidel Valea, Sharon Wilczynski

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Cervical carcinoma remains a health issue for women worldwide. Cervical cytology screening is the current method for early detection, and the NCCN Cervical Cancer Screening Clinical Practice Guidelines in Oncology provide direction for evaluating and managing this process, including clarified and revised recommendations on screening techniques and intervals and follow-up of abnormal screening results, including colposcopy. Human papillomavirus (HPV) DNA testing for primary cervical cancer has been approved by the FDA, and HPV DNA testing for high-risk virus types can also be used as a component of both primary screening and workup of abnormal cytology results. Colposcopy, along with colposcopically directed biopsies, has become the primary method for evaluating women with abnormal cervical cytologies. Special considerations for colposcopy performed during pregnancy are also discussed.

Original languageEnglish (US)
Pages (from-to)58-82
Number of pages25
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number1
StatePublished - Jan 2008


  • Biopsy
  • Cancer screening
  • Cervical cancer
  • Cold-knife conization
  • Colposcopy
  • Human papillomavirus testing
  • Intraepithelial neoplasia
  • Liquid-based cytology
  • Loop electrosurgical excision procedure
  • NCCN clinical practice guidelines
  • Pap test
  • Papanicolaou test

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Cervical cancer screening'. Together they form a unique fingerprint.

Cite this